
The phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial found the addition of tumor treating fields (TTFields) to paclitaxel did not provide a statistically significant improvement in overall survival (OS) vs paclitaxel alone for patients with platinum-resistant ovarian cancer, failing to meet its primary end point.



















![[Nurse recording dialysis] Credit: iStock](https://cdn.sanity.io/images/0vv8moc6/ajmc/d0325805e4fd25df9227eeacb118e8ccbaf0dd99-612x408.jpg?w=350&fit=crop&auto=format)












